Wednesday, November 11, 2026

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Walmart Inc. (WMT), AbbVie Inc. (ABBV) as well as two micro-cap stocks, Pioneer Bancorp, Inc. (PBFS) and Aspira Women's Health Inc. (AWHL). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Ahead of Wall Street

The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.

You can read today's AWS here >>> AI Trade Comes Back Post-CoreWeave Numbers

Today's Featured Research Reports

NVIDIA’s shares have underperformed the Zacks Semiconductor - General industry over the past year (-12.9% vs. -3.7%). Per the Zacks analyst, China's restrictions limit data center opportunities for the company, while customer concentration, rising investment needs, supply commitments and credit guarantees increase business risks. Intensifying competition adds uncertainty.

However, broad AI infrastructure demand, Blackwell Ultra adoption and the expanding Vera Rubin platform strengthen NVIDIA's growth prospects. Customer diversification, product leadership and expanding software opportunities support its outlook.

(You can read the full research report on NVIDIA here >>>)

Walmart’s shares have outperformed the Retail - Supermarkets industry over the past year (+21.4% vs. +20.4%). The Zacks analyst believes that the company benefits from its scale, value positioning and strong omnichannel model. Healthy traffic, e-commerce growth, expanding advertising and membership businesses, and international diversification support its growth prospects.

Yet, elevated operating costs, pharmacy-related sales pressure and heavy capital spending weigh on profitability. Price investments may constrain margins, while currency fluctuations add uncertainty.

(You can read the full research report on Walmart here >>>)

AbbVie’s shares have outperformed the Medical - Products  industry over the last six months (+41.4% vs. +28.4%). The Zacks analyst believes the company has offset Humira's patent-related sales decline with strong growth from Skyrizi and Rinvoq. Its expanding neuroscience portfolio, robust pipeline, new indication approvals and strategic acquisitions support long-term growth prospects.

However, Humira's continuing erosion, slowing oncology sales and macroeconomic pressures on its Aesthetics business remain significant challenges.

(You can read the full research report on AbbVie here >>>)

Pioneer’s shares have outperformed the Zacks Banks - Northeast  industry over the past year (+37.7% vs. +27.2%). The Zacks analyst believes that the company benefits from wider spreads, deposit and loan growth, specialty-finance expansion and diversified fee-based businesses. Generally stable asset quality and a solid capital position support growth initiatives.

Yet acquisition-related expenses, litigation risks, higher funding costs and rising charge-offs could pressure profitability. Capital-ratio compression may also limit financial flexibility.

(You can read the full research report on Pioneer here >>>)

Aspira’s shares have underperformed the Zacks Medical - Instruments  industry over the past year (-66.6% vs. +24.5%). The Zacks analyst believes that the company faces liquidity constraints, financing dependence and weakness in its core business. Its investment case remains highly execution-dependent, with significant risks surrounding commercialization and pipeline development.

However, ENDOinform targets an underserved market, while clinical validation and the Cleveland Clinic partnership offer growth potential. An established distribution network could also support future product launches.

(You can read the full research report on Aspira here >>>)

Other noteworthy reports we are featuring today include Morgan Stanley (MS), CVS Health Corp. (CVS) and General Dynamics Corp. (GD).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>